Comparing Chemotherapy for Biliary Tract Cancer
Author Information
Author(s): Kim Mi-Jung, Oh Do-Youn, Lee Se-Hoon, Kim Dong-Wan, Im Seock-Ah, Kim Tae-You, Heo Dae Seog, Bang Yung-Jue
Primary Institution: Seoul National University Hospital
Hypothesis
What is the efficacy of gemcitabine-based versus fluoropyrimidine-based chemotherapy in unresectable biliary tract cancer?
Conclusion
Both fluoropyrimidine-based and gemcitabine-based chemotherapy show similar efficacy in treating unresectable biliary tract cancer.
Supporting Evidence
- The overall response rate for first-line chemotherapy was 18.3%.
- The median overall survival was 8.7 months.
- The median progression-free survival was 4.3 months.
- Fluoropyrimidine-based regimens showed a trend towards better response rates and disease control rates.
Takeaway
Doctors compared two types of chemotherapy for patients with a specific type of cancer that can't be removed by surgery, and found that both worked about the same.
Methodology
This was a retrospective study reviewing patients treated with palliative chemotherapy for unresectable biliary tract cancer.
Potential Biases
Potential selection bias due to the exclusion of patients who received both treatments simultaneously.
Limitations
The study is retrospective and nonrandomized, which may introduce bias.
Participant Demographics
159 males (65%) and 84 females (35%), median age 60 years (range 26–81).
Statistical Information
Confidence Interval
95% CI for median OS was 7.4–10.0 months and for median PFS was 3.7–4.9 months.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website